New hope for controlling debilitating side effect of powerful cancer drugs
NCT ID NCT04305145
Summary
This study is testing if a drug called infliximab is better than standard steroid treatment at resolving severe diarrhea and colon inflammation caused by immunotherapy drugs in people with advanced skin cancer. About 42 participants with stage III or IV skin cancer who develop this serious side effect will be randomly assigned to receive either infliximab or steroids for about 7 weeks. The main goal is to see which treatment helps more patients achieve resolution of their symptoms without needing ongoing steroids.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.